Published in Cancer Weekly, July 28th, 1997
Anthra has already completed AD32 clinical studies in the U.S. in refractory CIS and a license application is planned for submission in the final quarter of 1997. When approved, AD32 will receive "orphan drug" status for this indication which will confer a seven year period of marketing exclusivity. Trials for the second indication are currently in progress and a license submission is scheduled for early 1999.
There are three...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.